Keiichi Masuya

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Philipp Holzer, Keiichi Masuya, Pascal Furet et al. · Journal of Medicinal Chemistry · 2015 · 202 citations · Full text

Dihydroisoquinolinone Derivative, Drug Target, Molecular Biology +18

Total Synthesis of (−)-Coriolin

Hajime Mizuno, Kei Domon, Keiichi Masuya et al. · The Journal of Organic Chemistry · 1999 · 98 citations

Bc-ring Unit, Diversity Oriented Synthesis, Bioorganic Chemistry +13

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Sébastien Jeay, Swann Gaulis, Stéphane Ferretti et al. · eLife · 2015 · 87 citations · Full text

Highly Regio- and Stereoselective [3+2] Cyclopentanone Annulation Using a 3-(Alkylthio)-2-siloxyallyl Cationic Species

Keiichi Masuya, Kei Domon, Keiji Tanino et al. · Journal of the American Chemical Society · 1998 · 79 citations

Engineering, Heterocyclic, Alkene Metathesis +14

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Pascal Furet, Keiichi Masuya, Joerg Kallen et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 77 citations

Molecular Pharmacology, Medicinal Chemistry, Drug Target +14